News

Preventive treatment with Hemlibra (emicizumab-kxwh) kept bleeding under control for nearly three years in people with mild or moderate hemophilia A without inhibitors. That’s according to long-term data from the Phase 3 HAVEN 6 trial (NCT04158648). The results build on earlier findings showing that Hemlibra effectively controlled…

The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union and will soon be marketed under the brand name Frehemgo. Developer Novo Nordisk announced in a company press release…

The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical trial testing MGX-001, the company’s experimental gene-editing therapy for hemophilia A. The Phase 1/2 trial, dubbed INTEGR8, aims to test the safety and tolerability of MGX-001 and identify optimal…

Note: This story was updated Nov. 12, 2026, to clarify that the art, IV Couture, was created with unused supplies; used needles are a biohazard. G Shellye Horowitz, an artist and advocate who writes the column The Forgotten Factor for Hemophilia News Today,  has been selected as a winner…

Once-weekly preventive treatment with Altuviiio (efanesoctocog alfa) safely reduced bleeding rates while maintaining protective clotting factor levels without triggering neutralizing antibodies in pediatric patients with hemophilia A. That’s according to a real-world study that reviewed data from 22 boys at the University…

Liver enzyme levels may rise again as corticosteroid doses are gradually reduced in people with hemophilia B treated with Hemgenix, a case report suggests. Elevated liver enzymes are a known side effect of the gene therapy that can signal liver inflammation or damage. Corticosteroids are used to treat…

By educating and empowering patients and their families, clinicians can help improve access to accurate diagnoses and care for women and girls affected by hemophilia. That’s the argument made by a pair of doctors in Belgium in a paper titled, “How I Identify and Diagnose Carriers of Hemophilia…

Treatment disruptions during the height of the COVID-19 pandemic were a substantial driver of psychological distress for people with hemophilia in China, causing more stress than the virus itself, a study found. The researchers said the findings underscore the importance of reliable access to treatments, especially self-administered ones, to…

Inno8, a potential oral treatment to prevent bleeds in people with hemophilia A, appears more potent and long-lasting than currently available injectable treatments in preclinical laboratory and animal studies, a study suggested. The candidate therapy, being developed by Novo Nordisk, is undergoing clinical testing and has completed…